Brought to you by 
Archemix licenses Gilead's aptamer technology
22 Jul 2002
Executive Summary
Archemix Corp. (nucleic acid engineering technology) acquired an exclusive worldwide license (including the right to sublicense) to Gilead Sciences' (cancer and infectious disease therapeutics) aptamer technology for $17.5mm; Gilead paid 5% of those proceeds to University Technology Corp. under a previous deal.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Archemix licenses Gilead's aptamer technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice